Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ck0001534133-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-
EX-99.1 2 ck0001534133-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the Phase 2b trial in acute pancreatitis will measure whether Auxora can reduce new-onset severe respiratory failure LA JOLLA, Calif., August 11, 2026 – CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today reported financial re...
Source
Exhibit EX-99.1
0001193125-26-343428
Filed August 11, 2026 at 11:15 AM UTC. The figures above are from the audited statements, not from this release.